Last reviewed · How we verify
AT02
AT02 is a small molecule that targets the SGLT2 receptor.
AT02 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | AT02 |
|---|---|
| Also known as | DHP-300 |
| Sponsor | Dhp Korea Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, AT02 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- The Impact of Treadmills and Cooler Environments for Office Workplaces on Ergonomics, Heating Energy Requirements, Performance, as Well as Back and Cardiometabolic Health (NA)
- Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS (PHASE2)
- Effects of Operational Naps on Blood Pressure and Performance Among Night Shift Workers (NA)
- A Study of AT-02 in Subjects With Systemic Amyloidosis. (PHASE2)
- Effect of Breast Milk Circadian Properties on Infant's Growth Parameters and Absorption of Nutrients (NA)
- Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis (PHASE1)
- Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AT02 CI brief — competitive landscape report
- AT02 updates RSS · CI watch RSS
- Dhp Korea Co., Ltd. portfolio CI